Global Healthcare: The Obesity Evolution

This report examines the global production capacity for Anti-Obesity Medication (AOM) peptides, specifically comparing Novo Nordisk's proprietary fermentation processes with synthetic (SPPS) manufacturing used by global CDMOs. It projects significant market growth for peptide API demand, largely driven by the adoption of oral GLP-1 therapies.

Key Takeaways

• 1.Novo Nordisk is expected to maintain a cost-advantage over generic competitors via proprietary fermentation-based API production vs synthetic (SPPS) methods used by CDMOs.
• 2.Global peptide API requirement is projected to rise significantly to 79,000 kg by 2030, driven largely by the transition to oral GLP-1 therapies.
• 3.Chinese CDMOs like Wuxi AppTec and Asymchem dominate global SPPS peptide API manufacturing capacity and are positioned to benefit from AOM market growth.

Table of Contents

• Company level considerations
• How much peptide API is needed to serve the Global AOM market?
• How much SPPS capacity is available for GLP-1 API production?
• Valuation and Risks